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ABSTRACT
Background
The use of fractionated stereotactic radiotherapy (FSRT)
has evolved with technical advances in noninvasive
immobilization, radiation delivery, and image guidance.
The application of FSRT to pituitary tumours is aimed
at reducing toxicity through improved dose conformality
and reduced treatment margins. The aim of the present
paper is to report our own experience and to review
the published data on FSRT for pituitary macroadenomas.
Methods
Between September 2000 and October 2005, 13 pa-
tients with pituitary macroadenoma underwent FSRT
at our institution. In 12 patients, radiotherapy treatment
followed surgical resection (transsphenoidal resection
in 8, frontal craniotomy in 3, and multiple trans-
sphenoidal resections followed by craniotomy in 1). In
4 patients, the tumours were functional (2 adrenocorti-
cotropic hormone–secreting, 1 prolactinoma, and 1
growth hormone–secreting); the tumours in the remain-
ing patients were clinically non-secretory. Before ra-
diation, 3 patients had panhypopituitarism, and 6 patients
had visual field defects. All patients were treated with
FSRT using non-coplanar micro–multileaf collimation
portals. A median dose of 50.4 Gy (range: 45–60 Gy)
was prescribed to the 76.9%–95.2% isodose surface and
delivered in 1.8-Gy fractions. The median planning tar-
get volume (gross tumour plus 3 mm) was 33.5 cm3
(range: 3.2–75 cm3).
Results
After a median follow-up of 24 months (range: 6–60
months), local control was 100%. One patient achieved
clinical complete response. Treatment was well toler-
ated acutely for all patients. Neither radiation-induced
optic neuropathy nor any radiation-related endocrine
dysfunction was observed in our patients.
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1. INTRODUCTION
Pituitary tumours account for 10%–15% of primary in-
tracranial neoplasms. “Macroadenoma” refers to a
tumour more than 10 mm in diameter 1. Typically, these
tumours extend superiorly into the suprasellar cistern
or laterally into the cavernous sinuses. In many cases,
despite early benefit from surgical debulking, long-term
cure from transsphenoidal surgery alone remains elu-
sive. Radiotherapy is frequently used to treat residual or
recurrent pituitary adenomas 2. In retrospective series,
immediate postoperative radiotherapy has clearly led to
significant improvements in long-term local control.
Nevertheless, concerns regarding potential late compli-
cations such as brain necrosis and optic nerve injury
have limited or delayed the use of radiotherapy 3,4. Clas-
sically, simple three-dimensional conformal plans (of-
ten a 3-field technique) were used to treat these central
lesions, resulting in significant dose delivery to the tem-
poral lobes and the optic apparatus.
With advances in noninvasive immobilization tech-
niques, sophisticated planning systems, and image guid-
ance, fractionated stereotactic radiotherapy (FSRT) has
supplanted three-dimensional conformal radiotherapy in
the treatment of macroadenomas. The FSRT technique
combines the similar dose conformality, precise dose
delivery, and steep dose falloff outside the target vol-
ume of stereotactic radiosurgery with the radiobiologic
advantages of dose fractionation. Fractionation safely
treats larger tumour volumes intimate to critical structuresELHATEER et al.
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such as the optic apparatus 3,5,6. Here, we report our ex-
perience of FSRT in a series of 13 patients whose pitui-
tary macroadenomas were in close relationship with the
optic chiasm or the cavernous sinus, or both.
2. PATIENTS AND METHODS
Between September 2000 and October 2005, 13 pa-
tients (9 men, 4 women) with pituitary macroadenoma
were treated with FSRT at the Montreal General Hos-
pital. These patients had a median age of 56 years
(range: 30–80 years). In 9 patients, the tumours were
non-secreting; tumours in the other 4 patients were
functional (2 causing Cushing disease, 1 causing ac-
romegaly, and 1 being a prolactinoma). Surgical re-
section was the initial treatment in 12 patients: 8 had
transsphenoidal resections, 3 had frontal craniotomies,
and 1 had multiple transsphenoidal resections followed
by craniotomy.
The indications for FSRT were postoperative re-
sidual disease in 5 patients (38.4%) at a median of 3.2
months from surgery (range: 1.2–7.4 months), recur-
rent disease in 7 patients (53.8%) at a median of 12.4
months from surgery (range: 5.2–53.3 months), and
primary therapy in 1 patient. Table I summarizes pa-
tient characteristics. All patients underwent complete
clinical evaluation before FSRT, including consultations
in ophthalmology and endocrinology.
A pretreatment 2-mm global T1 contrast-enhanced
magnetic resonance imaging (MRI) study was obtained
for all patients and co-registered to a 3-mm treatment
planning computed tomography scan. Tumour and nor-
mal structures were contoured, and a 3-mm margin
was then added to the gross tumour volume to gener-
ate the planning target volume (PTV). Treatment plans
were typically designed using 4–6 static 6-MV non-
coplanar micro–multileaf collimation portals (Brainscan
5.21: BrainLAB AG, Heimstetten Germany). Typically,
a dose of 50.4 Gy was prescribed to a median isodose
surface of 90.1% (range: 76.9%–95.2%) in 1.8-Gy frac-
tions over 5.5 weeks. A different regimen was used to
treat 2 patients: one patient was treated to 45 Gy; the
other, whose tumour had malignant features, received
60 Gy. Patients were immobilized using a noninvasive
thermoplastic mask system (BrainLAB AG), with the
patient supine in neutral head position.
Patients were followed regularly after treatment, 3
times during the first year, and then every 6 months there-
after. Follow-up included clinical assessment, MRI stud-
ies, and hormonal assays. When warranted, visual field
and formalized visual acuity testing was performed.
3. RESULTS
The median PTV for all 13 patients was 33.5 cm3 (range:
3.1–75 cm3). All patients had extrasellar tumour ex-
tension. In 2 patients (15.3%), extension reached the
suprasellar region, and in 11 patients (84.6%), it reached
the cavernous sinus.
The use of the stereotactic technique provided ap-
propriate conformation of the prescribed dose to the
PTV with a median planning isodose–tumour volume
conformity index of 1.4 (range: 1.2–1.8). Between
93.3% and 99.1% (median: 97%) of the PTV was cov-
ered by the prescription isodose. In all patients, a por-
tion of the optic chiasm and the optic nerves was spared
from receiving the prescribed radiation dose. Because
of proximity to the target, a small portion of the optic
apparatus could have received a dose equal to or slightly
higher than the prescribed dose. Hot spots of up to 110%
of the prescribed dose were on occasion delivered to
5%–16% of the volume of the optic chiasm or the optic
nerves. Figure 1 shows an averaged dose–volume his-
togram for all patients, and Table II summarizes the
treatment parameters.
Treatments were well tolerated. No acute effects
at grade 2 or higher were recorded, and to date, no late
toxicity has been observed. All patients completed the
prescribed radiation dose without treatment interruption.
TABLE I Patient characteristics
        Characteristic n (%)
Age (years)
Median 56
Range 30–80
Sex
Male 9 (69)
Female 4 (31)
Tumour type
Non-functioning 9 (69)
Prolactinoma 1 (8)
GH-secreting 1 (8)
ACTH-secreting 2 (15)
Indication for radiotherapy
Postoperative 5 (38)
Disease progression 7 (54)
Definitive 1 (8)
Tumour volume (cm3)
Median 13.5
Range 1.1–47.6
Pretreatment tumour extension
Suprasellar 2 (15)
Parasellar 11 (85)
Pretreatment hormonal status
Normal 6 (46)
Hypopituitarism 3 (23)
Oversecretion 4 (31)
Pretreatment visual status
Intact 3 (23)
Subjective visual symptom 4 (31)
Objective visual field defect 5 (38)
Oculomotor nerve injury 1 (8)
Presenting symptom
Visual 9 (69)
Hormonal 3 (23)
Headache 1 (8)
GH = growth hormone; ACTH = adrenocorticotropic hormone.FSRT FOR PITUITARY MACROADENOMAS
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At a median follow-up of 27 months (range: 10–82
months), the local control rate—defined as freedom
from radiologic disease progression—was 100%. In 2
patients (15.4%), an objective radiologic response was
achieved. Complete tumour resolution was achieved
in 1 patient with a large residual adrenocorticotropic
hormone (ACTH)–secreting macroadenoma. His fol-
low-up MRI study revealed no radiologic evidence of
disease 4 years after FSRT (Figure 2). Another patient
who received primary FSRT for a growth hormone–se-
creting adenoma achieved a partial (50% or better)
reduction in the original tumour volume. Radiologic
findings were stable in the other 11 patients.
Of the 4 patients with functional macroadenomas,
only 1 patient with an ACTH-secreting macroadenoma
showed hormone level normalization from the pretreat-
ment elevated level. This response was associated with
a complete radiologic response (Figure 2). No signifi-
cant change in hormone level was observed in the other
3 patients.
Pre-existing panhypopituitarism in 3 patients (23%)
required continued hormone replacement therapy dur-
ing and after FSRT. At last endocrinology follow-up, no
manifestations of pituitary insufficiency were observed
in the other 6 patients who presented with normal pi-
tuitary function.
Before the FSRT, 5 patients had an objective visual
field defect, and 1 patient had occulomotor nerve in-
jury. These original neurologic deficits were not
changed after radiation therapy. Furthermore, no ab-
normalities were seen in the follow-up visual assess-
ments of the remaining patients.
4. DISCUSSION
Surgical resection remains the initial treatment of choice
for symptomatic non-prolactin-secreting pituitary
macroadenomas 7,8. Surgery offers the advantages of
pathologic confirmation, immediate decompression of
the optic apparatus, and rapid reduction of pathologic
hormone secretion 7,9. Long-term tumour control rates
after surgery alone range between 50% and 80% 10.
However, a complete resection is achievable in only
44%–84% of patients with pituitary macroadenoma 11.
The risk of local recurrence after subtotal resection is
33%–80%. Postoperative fractionated radiation is
highly effective, leading to a 15-year local control rate
of 95% 9,12–14.
Despite well-established long-term tumour control
rates for adjuvant radiation therapy in pituitary
macroadenoma, use of radiation is limited or frequently
delayed because of concerns over potential late com-
plications involving the optic apparatus, the pituitary
gland, or the brain parenchyma 13,14. The most com-
mon complication after postoperative radiation therapy
is pituitary hormone deficiency, whose reported rate
ranges between 30% and 50% 15. The risk of develop-
ing hormone insufficiency is persistent for up to more
than 15 years after radiotherapy. Brada et al. reported
a need for hormonal replacement therapy in 30% and
50% of patients 10 and 19 years after radiotherapy 16.
Optic neuropathy is a serious complication, but it is
rare after fractionated radiotherapy to doses of 45–
54 Gy; Parsons et al. reported no optic nerve injuries
in 106 optic nerves that received a total radiation dose
of less than 59 Gy 17. The reported risk of optic neu-
ropathy after fractionated radiotherapy for pituitary ad-
enomas lies between 1% and 5% 3. Radiation-induced
secondary intracranial tumours in the form of
FIGURE 1   Cumulative representation of the average dose–volume
histogram of 13 patients with pituitary macroadenoma. PTV = planning
target volume; Rt = right; Lt = left.
TABLE II   Treatment parameters
                     Parameter Median a Range a
Planning target volume (PTV [cm3]) 33.5 3.1–75
Total dose (Gy) 50.4 45–60
Fractions (n) 28 23–33
Fields (n) 5 4–6
Prescription isodose surface (%) 90.1 76.9–95.2
Conformity index 1.4 1.2–1.8
Dose covering 99% of the PTV (%) 98 94–100
Maximum dose to the chiasm (Gy) 52.9 44.3–55.5
Mean dose to the chiasm (Gy) 42.6 18.6–49
Maximum dose to optic nerves (Gy) 51.2 17–55.4
Mean dose to the left optic nerve (Gy) 15.3 5–28.5
a   Average calculation for all patients.
FIGURE 2   Magnetic resonance imaging (MRI) in a 38-year-old man
with adrenocorticotropic hormone–secreting adenoma. (a)
Pretreatment image shows a large postoperative residual tumour.
(b) Follow-up image 4 years after fractionated stereotactic
radiotherapy shows complete response.ELHATEER et al.
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sarcomas, meningiomas, and gliomas were also re-
ported with cumulative risks of 1.3% and 1.9% after
10 and 20 years respectively 18. Other reported com-
plications include brain necrosis, cerebrovascular dis-
ease, and neurocognitive dysfunction, although these
risks are not well defined nor is the contribution of
radiation to these events 3,17,18.
The foregoing risk estimates are derived from
series in which less-conformal techniques were used
to deliver radiation therapy. The image-guided stere-
otactic techniques currently available allow for more
precise targeting, more-conformal dose distributions,
and steeper dose falloff beyond the target volume,
thereby reducing normal-tissue exposure and, conse-
quently, expected late toxicities. Figure 3 depicts the
dosimetric difference between conventional 3-field
and FSRT plans. Not only does the latter plan provide
better target coverage (the PTV is entirely within the
prescription isodose), but also significant sparing of
the optic chiasm.
Stereotactic radiosurgery (SRS), either Gamma
Knife (Elekta, Stockholm, Sweden) or linear accel-
erator–based, has frequently been used in the treatment
of pituitary adenoma, with crude local control rates
ranging from 90% to 100% and widely variable hor-
monal cure rates ranging from 0% to 100% 3,4. In a
recent retrospective comparison, no statistically sig-
nificant differences were observed between SRS and
conventionally fractionated conformal radiotherapy in
terms of objective response rate (81.8% at 4 years)
and local control rate (97% at 4 years). However, a
trend toward a higher complete hormonal response rate
was observed in the SRS group (43.8% vs. 36.4%), with
a shorter median time to complete hormonal remis-
sion (26 months in the SRS group and 63 months in the
fractionated radiotherapy group). No patients developed
FIGURE 3   Axial, coronal, and sagittal magnetic resonance imaging slices with isodose distributions from (a) conventional 3-field technique,
showing coverage of the planning target volume (PTV) and optic chiasm by the 95% isodose surface; and (b) 5-field fractionated stereotactic
radiotherapy technique showing coverage of the PTV by the 100% isodose surface, while keeping the optic chiasm (arrow) outside the 75%
isodose surface.FSRT FOR PITUITARY MACROADENOMAS
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new visual deterioration, and of 11 patients who re-
quired post-treatment hormone replacement therapy,
only 1 was in the SRS group 19.
Reports from retrospective trials of SRS specifi-
cally addressing pituitary macroadenoma show simi-
lar results 20,21, although in one series, macroadenomas
tended to have worse local control. Local failures were
also more common in cases in which the tumour ex-
tended into the cavernous sinus 20.
The limitation of SRS is radiation-induced optic
neuropathy after a single large radiation dose. The risk
is low with doses below 10 Gy, but it increases to 26.7%
at doses of between 10 Gy and 15 Gy. Doses higher
than 15 Gy are associated with a markedly increased
risk that may reach 77.8% 21. The current consensus is
to limit radiosurgery to smaller adenomas removed
from the optic apparatus (usually 3–5 mm) and to keep
the dose to the optic apparatus below 8–10 Gy 3.
Whether the outcomes for small tumours are different
for SRS and for fractionated radiotherapy remains con-
troversial. Treatment selection is often guided by insti-
tutional preference and treatment device rather than
by clinical evidence.
Currently, the use of FSRT is growing. The tech-
nique combines the precise treatment delivery of SRS
with the radiobiologic advantage of dose fractionation,
making it the preferred technique for the treatment of
large tumours or tumours closely situated to the optic
apparatus. In one of the earliest retrospective reports
on FSRT, Mitsumori et al. 22 reported the results of 30
patients treated with FSRT to a total dose of 45 Gy in 25
fractions, compared with 18 patients treated with SRS
to a dose ranging from 10 Gy to 18 Gy. The 3-year
tumour control rate was not significantly different
(100% for SRS and 85.3% for FSRT) The median tu-
mour volume in the SRS group was much smaller, at
1.9 cm3 as compared with 5.7 cm3 in the FSRT group.
The time to hormone normalization was shorter among
SRS patients, at 8.5 months as compared with 18 months
for FSRT patients. The authors reported no radiation-
induced visual complications in either group. The rates
of hormone deficiency after radiotherapy were not sig-
nificantly different (23% after SRS vs. 20% after FSRT).
The only significant difference noted was in the rate of
radiation-induced brain necrosis, which was 27.8% in
the SRS group as compared with 0% in the FSRT group
(p = 0.02). The authors recommended the use of FSRT
for pituitary adenoma whenever possible.
Table III summarizes the published data on FSRT
for the treatment of pituitary adenoma. Although the
proportions of macroadenoma in these series were not
specified, most series had to have included patients
with larger tumours, given the median tumour volume
range of 4.1–30.2 cm3.
Most studies have short follow-up periods. The
reported local control rate ranged from 85% to 100%.
The reported hormonal control rates are difficult to in-
terpret because the definition of hormonal control var-
ied with the study and because the number of patients
with secretory adenomas was small. The same uncer-
tainty applies to the reported visual complications,
which ranged from 0% to 7%. The dose to the optic
chiasm and the optic nerves, the types of visual com-
plications, and the methods used to diagnose those com-
plications were poorly reported in most studies.
In the current series, the median tumour volume
was 13.5 cm3 (range: 1.1–47.6 cm3), with most tu-
mours (84.5%) extending into the cavernous sinus. In
terms of local control, our early results with
macroadenomas are encouraging and comparable to
those reported in the studies described earlier. The data
are insufficient to draw conclusions with regard to hor-
monal response, given our relatively small and hetero-
geneous group of patients with secreting adenomas.
TABLE III   Summary of series on fractionated stereotactic radiotherapy
             Study                             Patients (n) with Median Median Median           Control (%)             Toxicity (%)
Non-functioning Functioning tumour volume dose follow-up Local Hormonal Visual Hormonal
tumour tumour (cm3) (Gy) (mo.)
Mitsumori et al., 1998 22 12 18 5.73 45 34 85.3 23 0 20
Milker–Zabel et al., 2001 23 42 20 a 30.2 50.4–52.2 38.7 93 25 7 4.8
Milker–Zabel et al., 2004 24 02 0  a 26.2 52.2 59.8 100 80 a 51 0
Cañón Rodríguez et al., 2005 25 24 32 8.9 54 51 92 NA 3.5 46
Colin et al., 2005 26 63 47 4.2 50.4 82 99 42.5 0 36.7
Paek et al., 2005 5 68 0 6.2 46–50.4 30 98 b — 2.9 6
Voduc et al., 2005 27 19 17 4.1 50.4 19.1 100 30 0 20
Minniti et al., 2006 28 67 25 12.2 54 32 98 b 36 1 22
Selch et al., 2006 29 33 6 10.5 48.6 32 100 0 0 19
McClelland et al., 2007 30 7 5 21.8 50.4 22.5 100 NA 00
Present study 9 4 13.5 50.4 27 100 25 0 0
a   Twelve patients replicated between these two studies.
b   Actuarial 5-year progression-free survival.
NA = not assessed.ELHATEER et al.
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5. CONCLUSIONS
Although studies with long-term follow-up are lack-
ing, FSRT appears to combine effective tumour control
with a low incidence of radiation-related morbidity in
patients treated for pituitary macroadenoma.
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